• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Hologic Inc.

    11/8/24 4:05:56 PM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email
    8-K
    HOLOGIC INC DE false 0000859737 0000859737 2024-11-05 2024-11-05

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    Current Report

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) November 5, 2024

     

     

    HOLOGIC, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

    DELAWARE

    (State or Other Jurisdiction of Incorporation)

     

    1-36214   04-2902449
    (Commission File Number)   (I.R.S. Employer Identification No.)

     

    250 Campus Drive, Marlborough, Massachusetts   01752
    (Address of Principal Executive Offices)   (Zip Code)

    (508) 263-2900

    (Registrant’s Telephone Number, Including Area Code)

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act.

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $.01 par value   HOLX   The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (e)

    Compensatory Arrangements of Certain Officers

    Approval of revised forms of Performance Stock Unit (“PSU”) Award Agreements. On November 5, 2024, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Hologic, Inc. (the “Company”) approved PSU Award Agreements for fiscal 2025. One form of PSU Award Agreement provides for vesting based on achievement of return on invested capital (“ROIC”) goals, one form of PSU Award Agreement provides for vesting based on three-year relative total shareholder return (“relative TSR”) and one form of PSU Award Agreement provides for vesting based on achievement of free cash flow (“FCF”) goals.

    The above descriptions of the PSU Award Agreements do not purport to be complete and are qualified in their entirety by reference to the applicable PSU Award Agreement, copies of which are attached to this report as Exhibits 10.1, 10.2 and 10.3 and are incorporated herein by reference.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number
       Description
    10.1    Form of Performance Stock Unit Award Agreement (ROIC) (adopted fiscal 2025)
    10.2    Form of Performance Stock Unit Award Agreement (relative TSR) (adopted fiscal 2025)
    10.3    Form of Performance Stock Unit Award Agreement (FCF) (adopted fiscal 2025)
    104    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 8, 2024     HOLOGIC, INC.
            By:  

    /s/ John M. Griffin

               

    John M. Griffin

    General Counsel

    Get the next $HOLX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    5/27/2025Hold
    Needham
    3/3/2025Buy → Hold
    Argus
    2/6/2025$80.00 → $75.00Outperform → Market Perform
    Leerink Partners
    2/3/2025Buy → Hold
    Needham
    12/13/2024Peer Perform
    Wolfe Research
    12/10/2024$90.00Buy
    Needham
    12/10/2024$85.00Hold
    Jefferies
    10/1/2024$95.00 → $85.00Buy → Neutral
    Citigroup
    More analyst ratings

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Div. President, GYN Surgical Schnittker Brandon covered exercise/tax liability with 69 shares, decreasing direct ownership by 1% to 6,094 units (SEC Form 4)

      4 - HOLOGIC INC (0000859737) (Issuer)

      6/3/25 4:19:30 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

      4 - HOLOGIC INC (0000859737) (Issuer)

      5/9/25 4:39:33 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • New insider Liddy Anne M. claimed ownership of 11,426 shares (SEC Form 3)

      3 - HOLOGIC INC (0000859737) (Issuer)

      5/2/25 4:52:34 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

      Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.holog

      7/2/25 4:05:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

      Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions Hologic, Inc. (NASDAQ:HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant clinical impact of the Breast Cancer Index® (BCI®) test, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025. "These data highlight the critical role the Breast Cancer Index test plays in guiding extended endocrine therapy decisions for women with early-stage, hormone

      5/22/25 5:05:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic Announces Financial Results for Second Quarter of Fiscal 2025

      – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share

      5/1/25 4:01:00 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 29, 2024 - FDA Roundup: October 29, 2024

      For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

      10/29/24 3:30:19 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • February 2, 2024 - FDA Roundup: February 2, 2024

      For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

      2/2/24 3:58:21 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

      4 - HOLOGIC INC (0000859737) (Issuer)

      5/9/25 4:39:33 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Hologic

      Needham reiterated coverage of Hologic with a rating of Hold

      5/27/25 1:53:30 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic downgraded by Argus

      Argus downgraded Hologic from Buy to Hold

      3/3/25 8:06:16 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Hologic from Outperform to Market Perform and set a new price target of $75.00 from $80.00 previously

      2/6/25 7:06:39 AM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    SEC Filings

    See more
    • SEC Form SD filed by Hologic Inc.

      SD - HOLOGIC INC (0000859737) (Filer)

      5/23/25 7:32:50 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • SEC Form 10-Q filed by Hologic Inc.

      10-Q - HOLOGIC INC (0000859737) (Filer)

      5/2/25 8:05:04 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HOLOGIC INC (0000859737) (Filer)

      5/1/25 4:02:02 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • CellMax Life Announces Expansion of Company Board With Leading Industry Experts

      Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

      4/6/23 9:00:00 AM ET
      $EXAS
      $HOLX
      Medical Specialities
      Health Care
      Medical Electronics
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics

    $HOLX
    Financials

    Live finance-specific insights

    See more
    • Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

      Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.holog

      7/2/25 4:05:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic Announces Financial Results for Second Quarter of Fiscal 2025

      – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share

      5/1/25 4:01:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

      Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2025 on Thursday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 6553890. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.hologic.c

      4/3/25 4:30:00 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hologic Inc.

      SC 13G/A - HOLOGIC INC (0000859737) (Subject)

      11/14/24 1:28:29 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • SEC Form SC 13G filed by Hologic Inc.

      SC 13G - HOLOGIC INC (0000859737) (Subject)

      2/14/24 10:04:34 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

      SC 13G/A - HOLOGIC INC (0000859737) (Subject)

      2/9/23 11:22:19 AM ET
      $HOLX
      Medical Electronics
      Health Care